ANDRES MANUEL R
CERVANTES RUIPEREZ
CATEDRÁTICO/A DE UNIVERSIDAD
University of Paris-Saclay
Gif-sur-Yvette, FranciaPublicaciones en colaboración con investigadores/as de University of Paris-Saclay (11)
2024
2023
-
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study
The Lancet Oncology, Vol. 24, Núm. 8, pp. 925-935
-
Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆
Annals of Oncology, Vol. 34, Núm. 1, pp. 10-32
-
Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer
ESMO Open, Vol. 8, Núm. 2
2019
-
Phase I study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) administered with PD-L1 inhibitor (atezolizumab) in advanced solid tumors
Clinical Cancer Research, Vol. 25, Núm. 11, pp. 3220-3228
-
Regorafenib dose escalations in the prospective, observational CORRELATE study in patients with metastatic colorectal cancer
Annals of Oncology, Vol. 30, pp. iv119
-
Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study
European Journal of Cancer, Vol. 123, pp. 146-154
2017
-
Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX
European Journal of Cancer, Vol. 82, pp. 16-24
2016
-
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Annals of Oncology, Vol. 27, Núm. 8, pp. 1386-1422
2014
-
Unmet needs and challenges in gastric cancer: The way forward
Cancer Treatment Reviews, Vol. 40, Núm. 6, pp. 692-700
2012
-
Esmo consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
Annals of Oncology, Vol. 23, Núm. 10, pp. 2479-2516